Dr. Kris Discusses Crizotinib in ALK-Positive Lung Cancer

Video

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial presented at the ESMO 2012 Congress that studied the use of crizotinib (Xalkori) in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).

Crizotinib prolonged progression-free survival (PFS) by 7.7 months compared to 3.0 months among patients treated with single-agent chemotherapy, either pemetrexed or docetaxel (HR 0.49; 95% CI 0.37—0.64 ; P < .0001). The overall response rate was also significantly higher in patients treated with crizotinib at 65% versus 20%. (P < .0001).

Kris believes that physicians should find confidence in both statistically significant data as well as the benefits demonstrated in a greater number of patients for the efficacy of crizotinib in ALK-positive NSCLC.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD